Activated T cells Inhibit NK Cell-mediated Tumour Rejection

Previous studies have described the regulation of some T-cell subsets toward natural killer (NK) cells. Naturally occurring CD4⁺CD25⁺ T regulatory cells can inhibit NK cell cytotoxicity, while activated interleukin-2 (IL-2) secreting T cells can stimulate NK cells. However, little is known about the...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of immunology 2009-04, Vol.69 (4), p.337-341
Main Authors: Wang, X.-J, Hu, J, Yuan, J, Peng, Y.-M, Gui, L, He, W.-F, Tan, J, Luo, G.-X, Wu, J
Format: Article
Language:English
Subjects:
Animals
Cell Communication - immunology
Coculture Techniques
Cytotoxicity, Immunologic - immunology
Immunologic Surveillance
Killer Cells, Natural - immunology
Lymphocyte Activation - immunology
Melanoma, Experimental - immunology
Mice
Mice, Inbred BALB C
Microscopy, Confocal
Rats
Rats, Wistar
T-Lymphocytes - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous studies have described the regulation of some T-cell subsets toward natural killer (NK) cells. Naturally occurring CD4⁺CD25⁺ T regulatory cells can inhibit NK cell cytotoxicity, while activated interleukin-2 (IL-2) secreting T cells can stimulate NK cells. However, little is known about the impact of the integrity T-cell population on the final outcome of NK cell cytotoxicity. We thus examined the possible role of activated T cells in affecting NK cell cytotoxicity by mixed lymphocyte co-cultures in vitro and a B16 melanoma tumour model in vivo. In our study, activated T cells were found to be able to significantly inhibit NK cell cytotoxicity in vitro and blunt NK cell-mediated tumour rejection in vivo. The inhibition of NK cell function is a cell-cell contact dependent way. Results suggest that activated T cells may play an important role in limiting NK cell functions, which might be very significant for the design of biotherapy against tumour or infection in future.
ISSN:0300-9475
1365-3083
DOI:10.1111/j.1365-3083.2009.02227.x